주요 건강 복지(보험) 기관으로 운영되는 Elevance Health Inc.는 소비자, 가족, 지역사회가 건강과 웰빙의 여정을 전 과정에 걸쳐 나아갈 수 있도록 안내하는 데 ...
이 글은 2028년 3월 1일 만기, 쿠폰 금리 4.10%의 Elevance Health, Inc. 채권 AE1K에 대한 핵심 지표를 제공합니다. 발행사의 사업 부문은 Health Benefits, CarelonRx, Carelon Services, Corporate & Other로 구성되어 있습니다. 해당 채권의 발행 잔액은 12.5억 달러(USD)이며 액면가는 1,000.00달러(USD)입니다.
Elevance Health, Inc.(ELV)는 2026년 7월 15일 2026년 2분기 실적을 발표할 예정이며, Zacks 애널리스트들은 전년 대비 실적과 매출 모두 감소를 전망하고 있습니다. 이 회사는 Health Benefits 부문 영업이익의 약세와 Commercial Individual 및 Medicaid의 가입자 감소로 인해 역풍에 직면해 있으며, 과거의 강한 서프라이즈 평균에도 불구하고 실적 상회 가능성은 불확실합니다. 또한 이 글은 다른 의료 부문 기업들인 ProMIS Neurosciences, Alcon Inc., Cardinal Health, Inc.가 실적 상회를 보고할 것으로 예상된다고 전합니다.
이 글은 고용주들이 약국 비용과 관련해 겪는 지속적인 문제를 다룹니다. 이는 자신들이 무엇을 위해 얼마를 지불하는지, 그리고 비용이 왜 증가하는지에 대한 가시성이 부족하기 때문입니다. 제안서에 제시된 약속된 절감과 실제 성과 사이의 격차, 높은 리베이트가 항상 실제 절감으로 이어지지 않는 이른바 "리베이트 환상", GLP-1s 같은 신약의 영향이 강조됩니다. 이 글은 약국 전략에 있어 사후 대응이 아니라 선제적이고 정보에 기반한 접근의 중요성을 부각합니다.
미즈호는 Elevance Health(ELV)의 목표주가를 $465에서 $470로 올리면서, 해당 주식에 대한 Outperform 등급을 재확인했습니다. 이번 조정은 Wells Fargo를 포함한 다른 애널리스트들의 Elevance Health 관련 조치와 함께 이루어졌으며, Wells Fargo 또한 회사의 목표주가를 상향 조정했습니다. 이 글은 Elevance Health에 대한 간단한 회사 프로필도 제공하며, 미국 시장에서 선도적인 헬스 보험사로서의 입지를 강조합니다.
웰스 파고는 엘리번스 헬스(EVL) 목표주가를 기존 391달러에서 492달러로 올리면서, 해당 주식에 대해 "비중확대(Overweight)" 등급을 재차 확인했습니다. 이번 조정은 동 관리 의료 회사에 대한 애널리스트 기업의 업데이트된 전망을 반영한 것입니다. 또한 이 기사에서는 엘리번스 헬스의 사업을 간략히 소개하며, 미국 시장에서 선도적인 건강보험사로서의 위치를 짚습니다.
이 글은 2028년 3월 1일 만기, 쿠폰 금리 4.10%의 Elevance Health, Inc. 채권 AE1K에 대한 핵심 지표를 제공합니다. 발행사의 사업 부문은 Health Benefits, CarelonRx, Carelon Services, Corporate & Other로 구성되어 있습니다. 해당 채권의 발행 잔액은 12.5억 달러(USD)이며 액면가는 1,000.00달러(USD)입니다.
Elevance Health, Inc.(ELV)는 2026년 7월 15일 2026년 2분기 실적을 발표할 예정이며, Zacks 애널리스트들은 전년 대비 실적과 매출 모두 감소를 전망하고 있습니다. 이 회사는 Health Benefits 부문 영업이익의 약세와 Commercial Individual 및 Medicaid의 가입자 감소로 인해 역풍에 직면해 있으며, 과거의 강한 서프라이즈 평균에도 불구하고 실적 상회 가능성은 불확실합니다. 또한 이 글은 다른 의료 부문 기업들인 ProMIS Neurosciences, Alcon Inc., Cardinal Health, Inc.가 실적 상회를 보고할 것으로 예상된다고 전합니다.
이 글은 고용주들이 약국 비용과 관련해 겪는 지속적인 문제를 다룹니다. 이는 자신들이 무엇을 위해 얼마를 지불하는지, 그리고 비용이 왜 증가하는지에 대한 가시성이 부족하기 때문입니다. 제안서에 제시된 약속된 절감과 실제 성과 사이의 격차, 높은 리베이트가 항상 실제 절감으로 이어지지 않는 이른바 "리베이트 환상", GLP-1s 같은 신약의 영향이 강조됩니다. 이 글은 약국 전략에 있어 사후 대응이 아니라 선제적이고 정보에 기반한 접근의 중요성을 부각합니다.
미즈호는 Elevance Health(ELV)의 목표주가를 $465에서 $470로 올리면서, 해당 주식에 대한 Outperform 등급을 재확인했습니다. 이번 조정은 Wells Fargo를 포함한 다른 애널리스트들의 Elevance Health 관련 조치와 함께 이루어졌으며, Wells Fargo 또한 회사의 목표주가를 상향 조정했습니다. 이 글은 Elevance Health에 대한 간단한 회사 프로필도 제공하며, 미국 시장에서 선도적인 헬스 보험사로서의 입지를 강조합니다.
웰스 파고는 엘리번스 헬스(EVL) 목표주가를 기존 391달러에서 492달러로 올리면서, 해당 주식에 대해 "비중확대(Overweight)" 등급을 재차 확인했습니다. 이번 조정은 동 관리 의료 회사에 대한 애널리스트 기업의 업데이트된 전망을 반영한 것입니다. 또한 이 기사에서는 엘리번스 헬스의 사업을 간략히 소개하며, 미국 시장에서 선도적인 건강보험사로서의 위치를 짚습니다.
엘리번스 헬스 주식은 전국적 입지를 바탕으로 상업·정부·특수 플랜 전반에 걸쳐 나타나는, 미국의 주요 관리형 케어 및 건강 혜택 플레이어를 대표합니다. 회사의 다각화된 모델은 고용주가 제공하는 보험과 메디케이드, 메디케어 어드밴티지 같은 정부 프로그램을 균형 있게 결합해 경기 변동 전반에 걸친 안정성을 제공합니다. 투자자들은 주식을 평가할 때 그 규모, 다각화된 사업 부문, 의료비와 규제 변화에 대응할 수 있는 능력을 고려합니다.
모리나 헬스케어(MOH)는 일리노이 HealthChoice 메디케이드 계약을 확보한 뒤, 최근 여러 러셀 지수에서 재분류됐습니다. 이 기사는 새로운 계약과 지수 변경이 모리나의 투자 스토리와 향후 수익에 어떤 영향을 미치는지 살펴봅니다. 특히 회사가 메디케이드 계약에 의존하는 점, 비용 통제, 정책 안정성을 강조하면서, 잠재적인 하방 위험도 함께 언급하고 공정가치 추정치도 제공합니다.
세인트루이스 기반 기업 C2N Diagnostics는 자사 PrecivityAD2 혈액 검사에 대한 첫 미국 보험 적용을 확보했습니다. 앤텀 블루 크로스 앤드 블루 쉴드는 10월 1일부터 자격이 있는 환자에게 알츠하이머 진단 검사를 보장하기 시작할 예정입니다. 이는 이 회사와 알츠하이머 진단에 대한 접근성 측면에서 중요한 이정표를 의미합니다.
This case study details how an organization drastically reduced musculoskeletal (MSK) health costs and improved employee wellbeing by implementing a comprehensive ergonomic redesign of all workstations. Key outcomes include a 20-30% reduction in employees experiencing MSK-related issues, a 45% reduction in claim volume, and a 23% reduction in total MSK spend, moving MSK from the second to the fifth-highest cost driver. Employee feedback also showed significant improvements in comfort, physical well-being, and productivity.
UnitedHealth Group (UNH) is currently favored among managed care stocks due to its strong performance and positive outlook ahead of its July 16 earnings report. The company significantly beat Q1 2026 EPS expectations by nearly 10%, raised its 2026 guidance, and analysts predict a 71% probability of another Q2 beat. Unlike competitors like Humana and Elevance Health, UNH has demonstrated superior repricing discipline and medical care ratio, making it an attractive blue-chip income stock for investors.
Wellpoint D.C. is exiting the city's Medicaid contract early, with AmeriHealth Caritas D.C. taking over all enrollees. Wellpoint CEO Dr. Tich Changamire will remain with the company through July as the transition occurs. This move consolidates D.C.'s Medicaid providers further, making AmeriHealth Caritas D.C. an even larger entity in the city's healthcare landscape.
Elevance Health Inc. (ELV) stock increased by 1.04% on Thursday, closing at $420.39, despite a generally favorable market day where the S&P 500 and Dow Jones also rose. However, the stock underperformed compared to its competitors. Elevance Health Inc. remains 1.59% below its 52-week high reached earlier in July.
Elevance Health (ELV) stock recently hit a 52-week high of $427.49, reflecting a 19.91% year-to-date return and a 23.23% increase over the past year. Despite this surge, InvestingPro analysis suggests the stock remains undervalued with a Fair Value of $475.42. The company has consistently raised its dividend for 15 consecutive years, and upcoming earnings on July 15th are keenly anticipated by analysts, with options data pointing to a potential 5.6% stock movement.
Elevance Health stock has reached a 52-week high of $427.49, reflecting a 19.91% year-to-date return and a 23.23% increase over the past year. Despite this, InvestingPro analysis suggests the stock remains undervalued with a Fair Value of $475.42 and has consistently raised its dividend for 15 years. Upcoming earnings on July 15 are anticipated to show positive results, with various analysts upgrading their ratings and price targets for the company.
Elevance Health (ELV) stock has reached a new 52-week high of $427.49, currently trading at $427.15, marking a 19.91% year-to-date return and a 23.23% increase over the past year. InvestingPro analysis suggests the stock is undervalued with a fair value of $475.42 and notes the company has raised its dividend for 15 consecutive years. Upcoming earnings are expected on July 15, with analysts projecting positive adjustments, and several firms have raised price targets or upgraded the stock due to stable market conditions and Medicaid trends.
RBC Capital Markets has raised its price target for Elevance Health (ELV) to $439, up from $358, while maintaining a "Sector Perform" rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also notes recent price target changes from other firms such as Evercore ISI, Cantor Fitzgerald, and Bernstein, indicating a general re-evaluation of Elevance Health's stock by financial analysts.
The article highlights how uncertainty in Congressional control, particularly due to shifts in the Maine Senate race, impacts policy-sensitive companies in healthcare, pharmaceuticals, and clean energy. It discusses UnitedHealth Group (UNH), Pfizer (PFIZER), and NextEra Energy (NEE), detailing their exposure to potential regulatory changes, financial pressures, and political volatility, urging investors to consider these risks.
Elevance Health Inc. is anticipated to see a 5.6% stock price movement when it reports earnings on July 15, according to options data analyzed by Bloomberg. Historical data shows that the actual price changes have varied significantly from the implied moves suggested by options in previous earnings announcements. For instance, while options implied a 6.2% move on January 28, the stock actually fell by 6.9%.
Options data suggests Elevance Health Inc. (ELV) shares could move 5.6% when the company reports earnings on July 15. Analysis of past earnings reports indicates that the actual stock price movement has sometimes exceeded or fallen short of the implied move from options data. Over the last eight earnings announcements, the stock's actual change has diverged significantly from the options-implied movement in several instances.
Elevance Health (ELV) is expected to report a year-over-year decline in earnings and lower revenues for the quarter ended June 2026. The market anticipates quarterly EPS of $6.18, a 30.1% decrease, and revenues of $48.45 billion, down 2%. Although the company has a Zacks Rank #2, a negative Earnings ESP suggests a difficult prediction for an earnings beat.
Elevance Health has filed a lawsuit against CMS and HHS, alleging that CMS unlawfully refused to recalculate its 2026 Medicare Advantage Star Ratings on the same basis provided to Clover Health. Clover Health previously won a court ruling forcing CMS to recalculate its star rating by excluding 20 quality measures, boosting its rating significantly. Elevance argues that this differential treatment is baseless and financially disadvantages them, seeking the same recalculation that would result in $115 million in additional Quality Bonus Payments and higher star ratings for five of its contracts.
This article reports on an SEC Form 144 filing by Elevance Health, Inc. (ELV) detailing a proposed sale of 1500 shares of common stock acquired through a stock award. The filing, dated July 7, 2026, indicates the sale will be conducted through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of $629,865.00.
An external audit of UnitedHealth's HouseCalls program, which provides home visits for Medicare seniors, found that almost 97% of diagnoses were supported by medical records, disproving accusations of inflating reimbursements. This error rate is significantly lower than the CMS's audit of privatized Medicare data. The findings bolster UnitedHealth's defense of the program, despite ongoing scrutiny and past government investigations into Medicare Advantage overpayments related to such home assessments.
Elevance Health Inc. (ELV) saw its stock rally by 2.62% to $418.85 on Tuesday, despite a generally negative trading session for the broader stock market, where the S&P 500 and Dow Jones Industrial Average both declined. The company's stock closed just shy of its 52-week high, indicating strong performance relative to its competitors. This strong trading day highlights Elevance Health's resilience in an otherwise grim market.
-
This July 2026 update details regulatory and legislative changes impacting several key areas. It covers developments in gender identity discrimination under the ACA, FLSA overtime exemption standards, the ERISA status of "Trump Accounts," and recent antitrust settlements for Blue Cross Blue Shield. The update also includes information on PCORI fee reporting, Massachusetts MCC standards for 2027, and mid-year increases in Paid Family and Medical Leave benefits in certain states.
Elevance Health will host a conference call and webcast on July 15, 2026, to discuss its financial results for the second quarter of 2026. The event will begin at 8:30 a.m. EDT and will be accessible via webcast on the company's website. A replay will also be available for those unable to attend live.
Elevance Health (NYSE: ELV) will release its second-quarter 2026 financial results on July 15, 2026, at 6:00 a.m. EDT. Management will discuss these results and provide their outlook during a conference call and live webcast scheduled for 8:30 a.m. EDT on the same day. A webcast replay will be available until August 14, 2026.
UnitedHealth Group (UNH) is shifting its focus from rapid enrollment growth to improving profitability due to a challenging operating environment. The company is repricing Medicare Advantage plans, exiting less profitable markets, and leveraging Optum's growth in value-based care and technology services. This strategic reset, showing early signs of success with improved first-quarter earnings and MCR, aims to restore earnings momentum and ensure long-term sustainability, an approach also being adopted by peers like Cigna and Elevance Health.
UnitedHealth (UNH) is shifting its strategy from rapid enrollment growth to focus on profitability due to higher healthcare utilization and rising Medicare Advantage costs. The company is repricing plans, exiting less profitable markets, and leveraging Optum as a growth driver through value-based care and technology. Peers like Cigna (CI) and Elevance Health (ELV) are also prioritizing efficiency and quality growth in a challenging healthcare environment.
CMS is proposing to expand its authority to revoke Medicare provider privileges as part of an effort to crack down on healthcare fraud, waste, and abuse. The proposed rule would allow CMS to remove providers for additional reasons, including operating in areas with an "excessive" number of providers, convictions related to sexual assault or financial misconduct, or issues with owners' licenses in other states. These changes, part of the Calendar Year 2027 Home Health Prospective Payment System Proposed Rule, aim to save taxpayers an estimated $82 million annually while also updating home health payments with a 2.4% increase.
Elevance Health Inc. (ELV) stock declined by 2.33% on Monday, closing at $408.17, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, indicating that Elevance Health underperformed its competitors and the market during this period. This drop ended a two-day winning streak for the stock.
UnitedHealth Group is a major player in the U.S. healthcare sector, integrating insurance and health services. The company's diversified model and involvement in public programs like Medicare and Medicaid are key factors for investors evaluating its long-term growth prospects. Its ability to balance growth with cost management in a highly regulated industry is also a significant consideration.
Centene Corporation is enhancing its fraud prevention efforts through advanced analytics and AI-enabled tools to improve profitability in its government-sponsored healthcare businesses. This strategy, particularly effective in Medicaid, helped increase Q1 2026 adjusted EPS by 16.2% and improved the Medicaid health benefits ratio. These initiatives aim to strengthen cost controls and provide a competitive advantage, with competitors like UnitedHealth Group and Elevance Health also focusing on similar strategies.
Centene Corporation is enhancing its fraud, waste, and abuse prevention strategies, using advanced analytics and AI, to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins in Q1 2026, leading to raised EPS guidance for the year. Competitors like UnitedHealth Group and Elevance Health are also focusing on similar AI-driven payment integrity measures.
Elevance Health is focusing on expanding its managed care and services portfolio by emphasizing digital tools, value-based care, and diversification across different health plans. The company aims to manage healthcare costs and improve member outcomes through these initiatives. It also invests in digital health tools and integrated health plans to strengthen member relationships and streamline care coordination.
Elevance Health has filed a lawsuit against the CMS, seeking a recalculation of its 2026 Medicare Star Rating. The insurer claims the CMS inconsistently applied rules by recalculating a competitor's (Clover Health) ratings after a court ruling, while denying the same treatment to Elevance, which it estimates will cost the company $115 million in 2027 quality bonus payments. Elevance argues that the same 20 measures deemed unlawful for Clover also impacted its own ratings and that all similarly situated parties should receive equal treatment under administrative law.
UnitedHealth Group Incorporated continues to emphasize its diversified portfolio of health benefits and services. The company's dual structure as both an insurer and a services provider, combining commercial, Medicare, and Medicaid plans with pharmacy benefits and data analytics, is a key feature. Investors are closely monitoring membership trends, medical cost management, and the company's role in the broader U.S. healthcare system.
Anthem Blue Cross and USA TODAY Network's GET Creative have partnered to launch a new five-part video series aimed at helping Americans better understand their health plan benefits, make informed care decisions, and manage costs. Hosted by Emmy and Critics' Choice Award-winning actress Katherine LaNasa, the series covers essential health insurance terms, choosing appropriate care settings, and strategies to avoid unexpected medical expenses. LaNasa, a breast cancer survivor and Anthem member, shares her personal experience to emphasize the importance of understanding healthcare options.
Anthem Blue Cross and Blue Shield and USA TODAY Network's GET Creative have launched a new five-part video series aimed at helping Americans understand their health plan benefits, make informed care decisions, and manage costs. Hosted by Emmy and Critics' Choice Award-winning actress Katherine LaNasa, the series covers essential health insurance terms, how to choose the right place for care, and strategies to avoid unexpected medical expenses. LaNasa, an Anthem member and breast cancer survivor, shared her personal experience to emphasize the importance of understanding healthcare options.
Alignment Healthcare (ALHC) recently reported strong quarterly results, showing 33.3% year-on-year revenue growth, better-than-expected EPS, and rapid membership gains, leading to a significant increase in its share price. Despite trading near analyst targets, the company is still considered undervalued by one intrinsic value estimate. The article highlights that Alignment's technology-enabled care model and investments in automation position it for future growth and margin expansion, though its success is dependent on supportive Medicare Advantage policies and controlled competition.
Elevance Health remains a key player in the US managed care sector, adapting its strategy to evolving regulations and market expectations. The company focuses on expanding in high-growth segments, improving medical cost management through technology, and diversifying into health services beyond traditional insurance. Elevance Health's integrated health benefits solutions aim to simplify member experience and coordinate care.
Molina Healthcare specializes in government-sponsored health plans, primarily focusing on Medicaid, Medicare, and Affordable Care Act (ACA) marketplaces. The company operates as a managed care organization, contracting with state agencies to provide health benefits to vulnerable populations, emphasizing care coordination and cost control. Its business model, which includes a diversified portfolio of government-related health plans, is attractive to investors interested in publicly funded healthcare.
Elevance Health (NYSE:ELV) shares fell before market open after the company lowered its full-year EPS guidance due to an expected increase in medical costs for the second quarter. The revised forecast puts its adjusted net income per share between $37.75 and $38.00, down from the previous range of at least $38.50. This announcement follows a similar warning from UnitedHealth (NYSE:UNH), which also noted higher medical costs, leading to broader sector concerns.
Molina Healthcare is focusing on its Medicaid and Medicare managed care business, which benefits from strong demand for government-sponsored health coverage in the U.S. The company's strategy emphasizes stable enrollment, disciplined cost management, and diversification through Medicare Advantage and health insurance marketplace plans. Success hinges on winning and retaining state and federal contracts, managing medical costs, and demonstrating quality outcomes.
Elevance Health, Inc. (ELV) has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS) after CMS allegedly unfairly altered a competitor's Medicare Advantage Star Ratings post-finalization. Elevance claims this cost them approximately $115 million in quality bonus payments and created an uneven competitive landscape. The company seeks to overturn CMS's decision and restore a consistent ratings process for all Medicare Advantage insurers.
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
CVS Health Corp. is expanding its integrated healthcare model, combining pharmacy, insurance, and clinical services to achieve long-term stability in the evolving U.S. healthcare landscape. The company's diversified approach, spanning retail pharmacies, pharmacy benefit management, and health insurance, aims to create a comprehensive care ecosystem. Investors are evaluating how effectively this integrated structure can translate into resilient earnings and improved patient outcomes through coordinated care.
Centene's integrated healthcare model, combining government health plans with clinical, pharmacy, and community-based services, is expected to support its earnings growth. The company serves 26.3 million members, allowing for economies of scale, and is leveraging technology and data analytics to manage costs and improve outcomes. Despite regulatory challenges, Centene's investments in technology and clinical programs are set to drive margin recovery and sustainable long-term earnings growth.
Elevance Health has filed a lawsuit against the Centers for Medicare and Medicaid Services (CMS) regarding the recalculation of the 2026 Medicare Advantage star ratings. The CMS plans to redo these star ratings for all insurance providers. The article highlights other related news in politics and regulation, including HHS freezing New York's Medicaid fraud unit funds and CMS proposing changes to hospital outpatient pay and 340B cuts.
